Literature DB >> 26310679

CORR Insights(®): Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?

Benjamin J Miller1.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26310679      PMCID: PMC4586198          DOI: 10.1007/s11999-015-4519-z

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


× No keyword cloud information.
  5 in total

1.  Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database.

Authors:  Kyle R Duchman; Yubo Gao; Benjamin J Miller
Journal:  Cancer Epidemiol       Date:  2015-05-20       Impact factor: 2.984

Review 2.  The role of radiotherapy in oseosarcoma.

Authors:  Rudolf Schwarz; Oyvind Bruland; Anna Cassoni; Paula Schomberg; Stefan Bielack
Journal:  Cancer Treat Res       Date:  2009

3.  Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?

Authors:  Zhengfu Fan; Shreyaskumar Patel; Valerae O Lewis; B Ashleigh Guadagnolo; Patrick P Lin
Journal:  Clin Orthop Relat Res       Date:  2015-07-22       Impact factor: 4.176

4.  Extremity soft tissue sarcoma resections: how wide do you need to be?

Authors:  David M King; Donald A Hackbarth; Andrew Kirkpatrick
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

5.  Adult soft tissue sarcoma local recurrence after adjuvant treatment without resection of core needle biopsy tract.

Authors:  Odion Binitie; Shawn Tejiram; Sheila Conway; David Cheong; H Thomas Temple; G Douglas Letson
Journal:  Clin Orthop Relat Res       Date:  2013-03       Impact factor: 4.176

  5 in total
  1 in total

1.  Primary Hepatic Osteosarcoma: A Rare Cause of Primary Liver Tumor.

Authors:  Tsering Gyalpo Lama Tamang; Marina Shuster; Abhinav B Chandra
Journal:  Clin Med Insights Case Rep       Date:  2016-04-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.